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Although probiotics have shown success in preventing the development of experimental colitis-associated
colorectal cancer (CRC), beneficial effects of interventional treatment are relatively unknown. Here we show
that interventional treatment with VSL#3 probiotic alters the luminal and mucosally-adherent microbiota,
but does not protect against inflammation or tumorigenesis in the azoxymethane (AOM)/Il102/2 mouse
model of colitis-associated CRC. VSL#3 (109 CFU/animal/day) significantly enhanced tumor penetrance,
multiplicity, histologic dysplasia scores, and adenocarcinoma invasion relative to VSL#3-untreated mice.
Illumina 16S sequencing demonstrated that VSL#3 significantly decreased (16-fold) the abundance of a
bacterial taxon assigned to genus Clostridium in the mucosally-adherent microbiota. Mediation analysis by
linear models suggested that this taxon was a contributing factor to increased tumorigenesis in VSL#3-fed
mice. We conclude that VSL#3 interventional therapy can alter microbial community composition and
enhance tumorigenesis in the AOM/Il102/2 model.
M
illions of individuals worldwide consume probiotic bacteria with the goal of improving gastrointestinal
(GI) health by restoring microbial homeostasis1. This is especially apparent among inflammatory bowel
disease (IBD) patients, totaling an estimated 1.4 million Americans and 2.2 million Europeans, who have
a high risk of developing colorectal cancer (CRC)2,3. Animal models and human clinical trials indicate that
probiotics may reduce inflammation and alleviate symptoms of IBD4, and it is tantalizing to consider that
beneficial effects may also extend to CRC. The majority of probiotic research has centered around effects on
the mammalian host with less emphasis on exploring the impact of probiotics on commensal microbes inhabiting
the GI tract, commonly referred to as the gut microbiota.
The gut microbiota is a population of an estimated 100 trillions of microbes that reside within the GI tract and
participate in a symbiotic relationship with their mammalian host. This population of microbes harbors 100-fold
more genes than are found in the human genome, and its enzymatic capacity rivals that of the human liver5.
Alteration in the composition of the gut microbiota, termed intestinal dysbiosis, is now regarded as a driving force
behind the pathogenic features of IBD and appears to similarly impact the development of CRC6–8. Culture-
independent rRNA sequence analyses have revealed differences in community composition of the luminal and
mucosally-adherent microbiota between human IBD patients and healthy controls9,10. Similar analyses on human
CRC patients have revealed significant differences in the luminal microbiota of cases vs. controls1,11, and differ-
ences in microbial community composition and richness in healthy rectal tissue from patients with adenomas
versus healthy controls2,12–14. Although it remains unclear which specific microbial taxa promote development of
inflammation and CRC, several bacterial groups have been consistently identified as altered in these disease states.
Bacteroidetes, a dominant phylum of the gut microbiota, were found to be less abundant in the tissue of adenoma-
bearing patients and human colorectal tumors relative to that of healthy controls4,13,15. Proteobacteria, in contrast,
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have been detected at increased abundance in human CRC
tissue5,12,13,16, tissue from IBD patients6–8,17,18, and in mouse models
of colitis and CRC8–10,19.
VSL#3 is a commercially available probiotic cocktail (Sigma-Tau
Pharmaceuticals, Inc.) of eight strains of lactic acid-producing bac-
teria: Lactobacillus plantarum, Lactobacillus delbrueckii subsp.
Bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifido-
bacterium breve, Bifidobacterium longum, Bifidobacterium infantis,
and Streptococcus salivarius subsp. Thermophilus. Orally adminis-
tered VSL#3 has shown success in ameliorating symptoms and redu-
cing inflammation in human pouchitis20,21 and ulcerative colitis22,23.
Preventive VSL#3 administration can also attenuate colitis in Il102/2
mice24 and ileitis in SAMP1/YitFc mice25. Nonetheless, several
reports indicate no beneficial effects of VSL#3 on murine dextran
sulfate sodium (DSS) colitis26, established ileitis in TNFDARE/1 mice27,
or human pouchitis28. The mechanisms underlying the beneficial
functions of VSL#3 are not well understood, but likely involve direct
effects of probiotic activity on the mammalian host as well as indirect
effects by altering the population dynamics of the gut microbiota as a
whole. Indeed, pre-treatment with VSL#3 altered community com-
position, prevented DSS colitis, and diminished adenoma and adeno-
carcinoma formation in the AOM/DSS model29,30. In the rat TNBS
model of inflammation-associated CRC, early administration of
VSL#3 altered microbial diversity and delayed the transition from
inflammation to dysplasia31,32. Thus it is clear that VSL#3 probiotic
has the capability to prevent inflammation and carcinogenesis when
used as a preventative strategy. However, the therapeutic potential of
VSL#3 probiotic administered after the onset of inflammation
remains unknown.
The goal of the present study was to assess the ability of probiotic
cocktail VSL#3 to alter the colonic microbiota and decrease inflam-
mation-associated cancer when administered as interventional ther-
apy. We report that therapeutic administration of VSL#3 probiotic
did not protect against the development of colitis-associated CRC or
inflammation in AOM/Il102/2 mice. In fact, we observed increased
tumorigenesis in one of two cohorts of VSL#3-fed mice, relative to
VSL#3-untreated mice. Illumina sequencing of this microbiota
revealed that microbial community composition of the stool and
mucosally-adherent compartments were significantly altered by
VSL#3 administration. Depletion of a bacterial taxon assigned to
genus Clostridium from the mucosally-adherent microbiota was
identified as a mediator of VSL#3-enhanced tumorigenesis in this
cohort. Together these findings demonstrate that therapeutic admin-
istration of VSL#3 does not protect against tumorigenesis in AOM/
Il102/2 mice and may promote the loss of potentially protective
microorganisms from the mucosally-adherent microbiota.
Results
VSL#3 does not protect against tumorigenesis in the AOM/Il102/2
model of colitis-associated CRC. To investigate the impact of
probiotic intervention on development of colitis-associated CRC,
we conventionalized germ-free (GF) Il102/2 mice with specific
pathogen free (SPF) microbiota for seven weeks to establish
intestinal inflammation. Conventionalizing mice born and raised
in GF conditions negates the confounding factor of familial
transmission of the microbiota. Tumorigenesis was then initiated
with 6 weekly i.p. injections of AOM (10 mg/kg), at which point
daily oral administration of VSL#3 (109 CFU/animal/day) was
begun (Fig. 1).
Based on previous reports showing that preventive administration
of VSL#3 can reduce dysplasia and tumorigenesis in experimental
models of inflammation-associated CRC30,32, we hypothesized that
interventional treatment would reduce tumorigenesis in the AOM/
Il102/2 model. However, macroscopic assessment of tumor pene-
trance revealed no significant effect of VSL#3 on tumorigenesis,
assessed seventeen weeks after the initial AOM injection (Fig. 2a).
Microscopic scoring of neoplasia revealed high-grade dysplasia in
18/19 mice, with no significant difference in dysplasia score between
VSL#3-treated and VSL#3-untreated animals (Fig. 2b). There was a
potential trend towards greater depth of tumor invasion in VSL#3-
treated animals that did not reach significance (Fig. 2c, chi-squared
test p 5 0.095).
To gain a better insight into VSL#3 effects on colitis-associated
CRC in respect to microbial composition, we repeated the experi-
ment using a second cohort of Il102/2 mice. Seventeen weeks after the
initiation of tumorigenesis with AOM, miniature endoscopy of live
anesthetized mice revealed large macroscopic lesions in VSL#3-
treated animals that were rarely seen in VSL#3-untreated animals
(Fig. 3a). Macroscopic examination of harvested colon tissue
revealed that VSL#3-treatment induced visible tumors in 91% of
mice, a significantly greater amount than the 38% observed in
VSL#3-untreated mice that developed macroscopic lesions (Fig. 3b,
c). Tumor multiplicity was also significantly enhanced by VSL#3,
Figure 1 | Experimental timeline for AOM/Il102/2 model with VSL#3
interventional administration. Germ-free Il102/2 mice were transferred to
SPF conditions where they were colonized with SPF commensal bacteria
for seven weeks. Tumorigenesis was then initiated with six weekly
injections of AOM (10 mg/kg), and VSL#3 was orally administered
(109 CFU/mouse/day) to mice daily throughout the remainder of the
experiment. After twenty-four weeks, mice were sacrificed and tissues were
harvested for assessment of microbiota, inflammation, and tumorigenesis.
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Figure 2 | VSL#3 does not affect tumorigenesis in AOM Il102/2 mice.
(a) Tumor penetrance, non-significant by one sample t test comparing SPF
1 VSL#3 group to SPF control at 100%, p 5 0.341 (b) dysplasia score, non-
significant by two-tailed Mann Whitney U test, p 5 0.315. Bar graphs
(a–b) depict mean 1 SEM. (c) Tumor invasion, comparisons by chi-
squared test, p 5 0.095. (a–c) SPF n 5 8, SPF 1 VSL#3 n 5 11.
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with an average of 1.64 macroscopic tumors per mouse vs. 0.33
tumors per mouse in VSL#3-untreated animals (Fig. 3d). Tumor size,
however, remained unaffected by VSL#3 treatment (Fig. 3e).
Histologic analysis of colonic sections revealed a significantly
enhanced dysplasia score in VSL#3-treated animals (Fig. 3f). As
observed in the first cohort, the cancer in VSL#3-fed animals was
highly penetrant, with nearly all animals exhibiting advanced neopla-
sia (Fig. 3g). The majority of the VSL#3-fed mice harbored invasive
adenocarcinomas (79% of mice), in contrast to only 13% of VSL#3-
untreated mice (Fig. 3h, i). These results indicate that interventional
treatment with VSL#3 does not protect against, and has the ability to
enhance, tumorigenesis and tumor invasion in the AOM/Il102/2
model of colitis-associated CRC.
VSL#3 treatment does not impact colonic inflammation in the
AOM/Il102/2 model. Chronic inflammation has been recognized
as an important risk factor for CRC. We next assessed histologic
inflammation in the distal and proximal colon of our second
cohort of AOM/Il102/2 mice treated with or without VSL#3. We
observed no significant difference in inflammation scores (Fig. 4a,
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Figure 3 | VSL#3 enhances tumorigenesis in a second cohort of AOM Il102/2 mice. (a) Miniature endoscopy, (b) macroscopic imaging, (c) tumor
penetrance, (d) tumor multiplicity, (e) dysplasia score, (f) individual dysplasia scores from the mice used for later microbiome (g) invasive
adenocarcinoma penetrance, (h) representative H&E histology. (a–e, g) Bar graphs depict mean 1 SEM, 13–14 mice/group, pairwise comparisons by
two-tailed Mann Whitney U test.
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b), demonstrating that intervention with VSL#3 does not alter
colonic inflammation. To gain greater insight into the inflamma-
tory environment of the colon, we measured inflammatory
cytokine mRNA in colon tissue biopsies using an Inflammation
PCR Array. There were no significant differences in the expression
of common IBD- and CRC-associated cytokines including Ifng, Il18,
Tnf, Il1b, Il23a, and Il6 (Fig. 4c). Together these results suggest that
VSL#3 enhances tumorigenesis without augmenting host inflamma-
tory status.
VSL#3 alters community composition of both the luminal/stool
and mucosally-adherent microbiota. Previous studies indicate that
IBD and CRC patients have a dysbiotic microbiota6,9,10,12,13. In
addition, we have previously demonstrated a bloom of Enterobac-
teriaceae in AOM/Il102/2 mice8. To determine the extent to which
VSL#3 alters the microbiota, we utilized Illumina HiSeq2000 high-
throughput sequencing. We extracted DNA from stool samples to
assess the luminal microbiota and from colon tissue biopsies to assess
the mucosally-adherent microbiota and sequenced the hypervariable
V6 region of the 16S rRNA gene8. We sequenced the luminal
microbiota of all animals, and one representative animal per cage
for the mucosally-adherent microbiota. We found that VSL#3
treatment altered both the luminal (ANOSIM R 5 0.381, P 5
0.032) and mucosally-adherent (ANOSIM R 5 0.406, P 5 0.024)
microbiota (Figure 5a). As expected, the composition of the luminal
compartment differed from that of the mucosally-adherent
microbiota (ANOSIM R 5 0.466, P , 0.001). Diversity of the
luminal and mucosally-adherent microbiota (Figure 5b and c)
were not significantly altered by VSL#3 treatment, although there
was a trend toward lower diversity in the luminal microbiota of
VSL#3-fed animals.
VSL#3 alters the abundance of specific bacterial taxa of the luminal/
stool and mucosally-adherent microbiota. To gain greater insight
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Figure 4 | VSL#3 does not significantly impact inflammation in AOM/
Il102/2 mice. (a) Distal, and (b) proximal colon histologic inflammation
scores, mean 1 SEM, 13–14 mice/group, pairwise comparisons by two-
tailed Student t test. (c) Colonic cytokine mRNA expression of four
individual SPF 1 VSL#3 mice relative to mean expression of four mice in
the SPF group; line at median. Data analysis was performed with
SABioscience RT2 Profiler PCR Array Data Analysis version 3.4 using the
DDCt method and two-tailed Student t test.
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Figure 5 | VSL#3 (filled symbols) alters community composition of the
luminal/stool (blue circles) and mucosally-adherent (red squares)
microbiota. (a) Operational taxonomic unit (OTU) abundances were
standardized by total, log-transformed, and assembled into a Bray Curtis
similarity matrix to generate a multidimensional scaling (MDS) plot,
where each symbol represents the microbiota of an individual mouse
analyzed by Illumina sequencing of V6 16S. Analysis of similarity
(ANOSIM) was used to test for dissimilarity between groups, where R 5 1
is maximum dissimilarity. As expected, the luminal/stool microbiota
differs from that of the mucosally-adherent microbiota, regardless of
VSL#3 treatment (ANOSIM stool vs. adherent, R 5 0.466, P , 0.001).
(b–c) VSL#3 does not affect Shannon diversity, Margalef richness or Pielou
evenness of the (b) mucosally-adherent or (c) luminal microbiota. Bar
graphs depict the mean diversity, richness or evenness of (b) mean 1 SEM;
SPF 5 5 mice, SPF 1 VSL#3 5 4 mice, or (c) cage means 1 SEM (to correct
for cage effects); SPF 5 10 mice in 4 cages, SPF 1 VSL#3 5 14 mice in 5
cages. (b–c) Pairwise comparisons were made using Student t test.
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into the microbial changes elicited by VSL#3 administration, we used
BLASTn36 to map the operational taxonomic unit (OTU) consensus
sequences to the Silva database (http://www.arb-silva.de/) and
classified the reference sequences using the RPD classifier37. In both
the luminal/stool and mucosally-adherent compartments, VSL#3
administration altered the phylum-level distribution of the micro-
biota, with differences achieving significance at a false discovery rate
(FDR) , 10% (Figure 6). VSL#3-treated animals exhibited a
significant contraction of Verrucomicrobia and expansion of Proteo-
bacteria in the mucosally-adherent microbiota. Within the luminal/
stool microbiota, the abundance of Bacteroidetes was significantly
decreased by VSL#3 treatment while Proteobacteria remained
unaffected. To determine which specific microbial groups may be
altered by VSL#3 treatment, we assessed the family-level distribution
of the luminal/stool and mucosally-adherent microbiota. We were able
to classify , 99% of reference sequences mapped to our OTUs to
family level. At both the luminal/stool and mucosally-adherent
compartments, VSL#3 treatment induced a contraction of Porphyro-
monadaceae and in the adherent compartment, also a contraction of
Verrucomicrobiaceae (Figure 7). These changes were significant at P
, 0.05 but not , 10% FDR, likely due to the large number of
microbial families surveyed. Depletion, rather than expansion, of
specific microbial groups in response to VSL#3 treatment suggests
that a loss of protective microbes contributed to the significantly
enhanced penetrance and severity of tumorigenesis in this model.
Depletion of a Clostridium bacterial group is associated with
VSL#3 administration and tumorigenesis. To determine if micro-
bial alterations in the mucosally-adherent microbiota mediate the
effects of VSL#3 on tumorigenesis, we performed mediation by
linear models analysis40 (Figure 8a and Methods section). In this
analysis, we first tested the effect of VSL#3 on dysplasia (model 1).
In agreement with earlier results presented in Figure 2, we found that
VSL#3 was significantly associated with dysplasia score (P , 0.0008).
We next applied model 2 to test the association of the relative
abundance of all OTUs of the mucosally-adherent microbiota with
dysplasia. We found that only a single taxon of the mucosal niche,
OTU#199, had a significant association with dysplasia score
(Benjamini and Hotchberg FDR corrected p 5 0.0518). The
consensus sequence of OTU#199 has an exact match to 38 distinct
Clostridium taxa in the Silva database, and all of these full-length
sequences were classified as Clostridiaceae I by RDP with a
confidence score of 99% and Clostridium sensu stricto with a
confidence score of 52%.
We next applied model 3, which indicated that VSL#3 treatment
was associated with a significant (,16 fold) decrease in the relative
abundance of OTU#199 (FDR corrected P 5 0.0525; Figure 8b).
Although the relative abundance of one other OTU of the muco-
sally-adherent microbiota was reduced in VSL#3 treated mice (FDR
corrected p 5 0.00073), model 2 analysis revealed that this OTU
(best classified as Blautia sp., accession GQ493997.1.1354) was not
associated with dysplasia (FDR corrected p . 0.10). From these
combined results, we concluded that depletion of a mucosally-adher-
ent Clostridium group was a potential mediator of the effects of
VSL#3 on dysplasia/tumorigenesis.
To further evaluate this possibility, we applied model 4. We tested
the effect of VSL#3 on dysplasia score without the influence of
OTU#199, and found a high P-value (0.9399), which indicates that
VSL#3 treatment is not directly associated with dysplasia. In con-
trast, when we tested the effect of OTU#199 on dysplasia score
without the influence of VSL#3, we found a low P-value (FDR cor-
rected P 5 0.0692), supporting that the abundance of OTU#199 is
associated with dysplasia. Taken together, the combined results of
this mediation analysis by linear models indicated that depletion of
OTU #199, a bacterial group of the genus Clostridium, is a potential
mediator of the effects of VSL#3 on dysplasia/tumorigenesis in our
experiment. These results demonstrate that VSL#3 may enhance
dysplasia/tumorigenesis through depletion of Clostridium bacteria
(OTU#199) at the mucosal niche.
Discussion
Intake of probiotics as a means to maintain health and alleviate
disease symptoms, especially gastrointestinal disorders, has gained
tremendous popularity worldwide. Although some of the beneficial
impacts of probiotics have been scientifically documented, mechan-
isms of action and impact on established disease remained unclear.
Introduction of billions of bacteria in a confined ecosystem such as
the intestine is likely to impact the microbial community. Earlier
work employing molecular fingerprinting analyses, including ter-
minal restriction fragment length polymorphism (TRFLP) and dena-
turing gradient gel electrophoresis (DGGE), have revealed that
administration of VSL#3 probiotic can alter microbial community
composition of mice and rats23,29,43,44. To better understand the
impact of interventional VSL#3 administration on the microbial
community during development of colitis-associated CRC, we uti-
lized high throughput Illumina 16S sequencing of the intestinal
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Figure 6 | VSL#3 alters the phylum-level distribution of the (a) luminal/
stool and (b) mucosally-adherent microbiota. Pie charts depict median
standardized abundance (% of total) of the indicated phyla. (a) Standardized
abundances of taxa contributing . 1% were log-transformed, pairwise
comparisons were made using Student t test, and P-values were FDR
corrected for multiple testing using the Benjamini and Hochberg procedure.
SPF 5 5 mice, SPF 1 VSL#3 5 4 mice. (b) Luminal/stool standardized log-
transformed abundances were compared using a one way ANOVA by fitting
a linear mixed model as described in Materials and Methods and P-values
were corrected for multiple testing as in (a). SPF 5 10 mice in 4 cages, SPF 1
VSL#3 5 14 mice in 5 cages.
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microbiota of AOM/Il102/2 mice. Interventional administration of
VSL#3 altered the composition of the luminal and mucosally-adher-
ent microbiota with phylum level changes in the luminal microbiota
(decrease in Bacteroidetes) and mucosally-adherent microbiota
(decrease in Verrucomicrobia and increase in Proteobacteria).
Depletion of specific bacterial groups at the family level, with
Verrucomicrobiaceae in the adherent compartment and Porphyro-
monadaceae in the luminal and adherent compartments, was
observed in VSL#3-exposed mice. Although we detected a non-sig-
nificant increase in the abundance of VSL#3 bacterial groups
Firmicutes and Lactobacillaceae, the major differences were detected
in non-VSL#3 bacterial groups, indicating that administration of
VSL#3 can exert pressure to induce broad changes in the microbial
population of the intestine. These findings clearly demonstrate that
VSL#3 administration markedly changed the composition of both
the luminal and mucosally-associated microbiota.
An unexpected consequence of interventional administration of
VSL#3 probiotic was the lack of a protective effect on tumorigenesis
and the propensity to enhance tumor invasion in AOM/Il102/2 mice.
We have previously demonstrated that inflammation in Il102/2 mice
alters the composition of the intestinal microbiota with expansion of
Proteobacteria, and this impacts the development of CRC8. In the
current study, VSL#3 was therapeutically administered after the
onset of inflammation and in the context of a dysbiotic microbiota.
In contrast to other studies where prophylactic VSL#3 administra-
tion ameliorated colitis and colitis-associated CRC24,29,30,32,45, our
results have demonstrated that administration of VSL#3 beginning
after the onset of inflammation and dysbiosis can enhance tumor-
igenesis. This was not associated with changes in inflammation or
inflammatory cytokine profiles. Instead, enhanced tumorigenesis
was associated with shifts in the composition of the intestinal micro-
biota in both the luminal/stool and mucosal niches. The initial com-
position of the microbial community likely influences probiotic
effects on the host, as we also observed that prophylactic administra-
tion of VSL#3 beginning 3 days after transfer of Il102/2 mice from
germ-free to SPF housing did not ameliorate inflammation nor early
dysplasia (data not shown). In fact, we observed unexpected mortal-
ity in this treatment group, and terminated the experiment early at
fourteen weeks post-transfer to SPF, six weeks after beginning AOM
treatment (SPF vs. prophylactic VSL#3, log rank test p 5 0.040).
Altogether, these results suggest that probiotics may be ineffective
and even detrimental to host health in the context of an immature or
dysbiotic microbiota.
It also appeared that administration of VSL#3 predominantly
induced depletion of bacterial groups, suggesting that tumorigenesis
was enhanced through the loss of protective commensal bacteria. To
determine if specific bacterial groups (classified into OTUs of 97%
similarity) of the mucosally-adherent microbiota mediated the
SPF
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Figure 7 | VSL#3 alters the family-level distribution of the (a) luminal/stool and (b) mucosally-adherent microbiota. Pie charts depict median
standardized abundance (% of total) of the indicated phyla. (a) Standardized abundances of taxa contributing . 1% were log-transformed, pairwise
comparisons were made using Student t test, and P-values were FDR corrected using the Benjamini and Hochberg procedure. SPF 5 5 mice, SPF 1 VSL#3
5 4 mice. (b) Luminal/stool standardized log-transformed abundances were compared using a one way ANOVA by fitting a linear mixed model as
described in Materials and Methods and P-values were corrected for multiple testing as in (a). SPF 5 10 mice in 4 cages, SPF 1 VSL#3 5 14 mice in 5
cages.
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effects of VSL#3 administration on tumorigenesis, we utilized a stat-
istical approach termed mediation by linear models40. This approach
first revealed that at a FDR corrected cutoff of P , 0.1, only one OTU
of the mucosally-adherent microbiota, belonging to genus
Clostridium, was a potential mediator of VSL#3 effects on tumori-
genesis in our model. Clostridium sensu stricto, the sub-genus to
which RDP classified this OTU with 52% confidence, is the largest
sub-genus of Clostridium and comprises approximately 73 spe-
cies46–48. Several of these species matched the consensus sequence
of OTU#199 at 100% identity in the Silva database. Clostridium
species have recently been shown to provide protection by inducing
IL-10-producing intestinal T-regulatory cells, however, this trait is
mainly attributed to Clostridium cluster IV and XIVa49. A major
mechanism by which T-regulatory cells maintain homeostasis in
the intestine is through the production of IL-1050,51. This protective
mechanism is not intact in Il102/2 mice, thus it is unlikely that
depletion of IL-10-producing T-regulatory cells is responsible for
enhanced tumorigenesis in VSL#3-treated AOM/Il102/2 mice. An
IL-10-independent mechanism of protection in the intestine is
consistent with early work in which colitis was prevented in
Il102/2 mice by prophylactic administration of VSL#3, which was
associated with an enhancement of epithelial barrier function24. At
this time, the impact of VSL#3 and depletion of Clostridium species
on epithelial barrier function in our colitis-associated CRC model is
unknown. In addition, future studies will be necessary to determine if
VSL#3 induces the depletion of Clostridium species in other CRC
models and in the absence of disease in healthy WT mice. Many
Clostridium can ferment dietary fiber and host mucins to produce
short chain fatty acids such as butyrate. Butyrate serves as a primary
energy source for healthy colonocytes and regulates gene expression,
inflammation, differentiation, and apoptosis in the intestine52–54.
Butyrate and butyrate-producing bacteria have anti-inflammatory
and anti-carcinogenic activities55–58, and butyrate-producing bacteria
are depleted in human IBD and CRC6,59,60. Thus depletion of
Clostridium OTU#199 from the mucosally-adherent microbiota
may reduce the production of butyrate and its anti-carcinogenic
effects, resulting in enhanced tumorigenesis in AOM/Il102/2 mice.
Butyrate and other short chain fatty acids are notoriously difficult to
measure in vivo61, however, if this hypothesis is correct, restoring the
availability of butyrate in the intestine via prebiotic and/or novel
probiotic supplementation with Clostridium could reveal a novel
means by which to protect against IBD and CRC. Future studies will
be necessary to determine if supplementation with any of the numer-
ous bacteria represented by OTU#199 can promote protection or
prevent VSL#3-induced enhancement of tumorigenesis in the
AOM/Il102/2 model.
Together, our findings highlight several important concepts. First,
probiotic bacteria may fail to protect against tumorigenesis in an
environment with established dysbiosis. Earlier studies have revealed
that VSL#3 probiotic can provide protection against colitis and col-
itis-associated CRC when VSL#3 is administered prior to the onset of
inflammation24,25,29,30,32,43,62. VSL#3 bacteria can mediate protection
in part through induction of IL-1063, which is absent in our system
and also in a subset of human IBD patients64–66. Thus it is possible
that IL-10-independent effects of VSL#3 administration are not suf-
ficient to overcome the pro-inflammatory and pro-carcinogenic
effects of established dysbiosis in the AOM/Il102/2 model. Second,
probiotic bacteria can alter the composition of the luminal and
mucosally-adherent microbiota and induce the depletion of endo-
genous beneficial microbes at the mucosal niche. In the current
study, we observed a detrimental effect that was potentially mediated
by the loss of Clostridium bacteria. Given the complexity in the
microbiota, it is not surprising to find evidence that certain bacteria
may protect against inflammation while others protect against the
progression of neoplasia. Undoubtedly, greater accessibility of new
‘omics technologies will allow for a better understanding of the tre-
mendous metabolic capacity of the microbiota and how microbial
activities can be modulated to promote health and protect against
disease.
Methods
AOM/Il102/2 model and probiotic administration. Il10-deficient 129/SvEv mice
were born and raised in germ-free (GF) isolators and then transferred directly to our
specific pathogen free (SPF) facility (age 7–12 weeks, housed 2–4 mice per cage)
for the immediate initiation of our colitis/colorectal cancer experiment (Fig. 1).
In this model, mice naturally acquire the microbiota from their cage/room
microenvironment. This method of conventionalization negates any confounding
familial or maternal transmission of the microbiota. We have recently characterized
the microbiota of this model38. After 7 weeks of colonization with SPF bacteria, mice
received 6 weekly i.p. injections of azoxymethane (AOM, 10 mg/kg). On the day of
the first AOM injection, one group of mice was orally administered VSL#3 probiotic
(Sigma-Tau Pharmaceuticals, Inc.), 109 CFU per animal each day during the week,
with two days off on weekends, until the end of the experiment. The second group was
not administered VSL#3 probiotic. After 17 weeks (24 weeks post-transfer from GF
housing), miniature endoscopy was performed to visualize tumor development in live
mice31. Mice were sacrificed, stool and tissue were collected, and colons were
examined macroscopically for tumors then swiss-rolled and fixed in formalin for
paraffin embedding and histology31. Histology was scored for inflammation33 and
dysplasia/tumors8 by two blinded experienced investigators and reviewed by an
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Figure 8 | Depletion of mucosally-adherent Clostridium bacteria
mediates the effects of VSL#3 on dysplasia/tumorigenesis. (a) Mediation
analysis by linear models was performed between VSL#3 status, dysplasia
score, and each OTU in the stool or mucosally-adherent microbiota.
Results for OTU #199 are shown. P , 0.10 was used as cutoff. The
Benjamini and Hotchberg FDR adjustment was applied for multiple
testing correction (model 2). A detailed description of the models is
provided in Materials and Methods. (b) OTU #199, assigned to genus
Clostridium, median log-normalized abundance 1 SEM. FDR-corrected
P-value is shown, uncorrected P-value 5 0.0002. SPF n 5 5, SPF 1 VSL#3
n 5 4.
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expert animal histopathologist. Dysplasia scoring was as follows: 0 5 no dysplasia; 1
5 mild dysplasia characterized by aberrant crypt doci (ACF), 10.5 for multiples; 2 5
gastrointestinal neoplasia (GIN), 10.5 for multiples; 3 5 adenoma, non-invasive
severe or high grade dysplasia restricted to the mucosa; 3.5 5 adenocarcinoma,
invasive through the muscularis mucosa; 4 5 adenocarcinoma, fully invasive through
the submucosa and into or through the muscularis propria. Two independent
experiments were conducted and data from both experiments are presented and
discussed. All animal protocols were approved by the Institutional Animal Care and
Use Committee of the University of North Carolina at Chapel Hill.
DNA extraction. Stool samples and mucosal biopsies were collected to assess luminal
and mucosally-adherent microbiota respectively. Colon biopsies (2 3 10 mm) were
collected after flushing the colon with PBS. Samples were immediately stored at
280uC. DNA was extracted from between 50–200 mg of stool or 100 mg colon tissue
as described8.
Illumina V6 16S library construction. The V6 hypervariable region of the 16S rRNA
gene was amplified using a two-step PCR strategy8. The first step uses primers to the
V6 region of the 16S gene that contain a 4–6 nucleotide barcode for multiplexing. The
subsequent PCR adds Illumina paired-end sequencing adapters and a flow-cell
adapter on the 59 and 39 ends of the amplicon. Amplicons were visualized on 1.5%
agarose gel and purified using the QIAquick PCR purification kit (Qiagen). 50 ng of
DNA from each sample was pooled to a final concentration of 29 ng/ul and subjected
to paired-end Illumina HiSeq2000 sequencing at the University of North Carolina
High Throughput Sequencing Facility.
Illumina sequencing. A single lane of Illumina HiSeq2000 generated 57,184,070
paired end sequences (144 multiplexed samples, 33 for this study) with a read length
of , 75 bases, excluding primer sequences. Raw sequences were processed as
described8 except that we required at least 70 continuous matching nucleotides across
the length of the ungapped alignment to generate each consensus sequence. A total of
39,537,745 paired-end sequences met our merging and extending criteria for the
whole lane and 8,532,581 sequences belonged to the current study. Those 8,532,581
consensus sequences were fed in three batches into the program AbundantOTU v.2.0
(http://omics.informatics.indiana.edu/AbundantOTU/) with default parameters34.
The first batch represented all 33 samples, the second represented only luminal/stool
(LS) samples (24 samples, 5,568,718 consensus sequences) and the third represented
mucosally-adherent (MA) samples (9 samples, 2,963,863 consensus sequences).
AbundantOTU clustered these sequences into 1,064 (all), 439 (LS) and 857 (MA)
Operational Taxonomic Units (OTUs). AbundantOTU incorporated 8,512,390
(99.76%) of all consensus sequences, 5,548,738 (99.64%) of the LS samples and
2,957,301 (99.78%) of the MA samples. The sequences that were not incorporated
into an OTU were excluded from further analyses. A UCHIME v. 4.2.40 (http://
www.drive5.com/uchime/35) search using the Gold reference database was used to
detect the presence of chimeras in our OTUs. UCHIME reported 6 (all), 3 (LS) and 2
(MA) chimeras representing a negligible fraction of the total consensus sequences
that were incorporated into OTUs. All reported chimeras were excluded from further
analyses.
To facilitate taxonomic classification and to compensate for the short read length of
the generated OTUs, we used BLASTn (v. 2.2.26136) with an expectation value
threshold of e-5 to map the OTU sequences to the Silva database (release 108, http://
www.arb-silva.de/). Next, we utilized the standalone version of the RDP classifier (v.
2.5 37) to classify the full-length Silva sequences with the best BLASTn match to the
OTU sequence requiring an RDP confidence score of $ 80%.
Given the short read length of our Illumina V6 amplicon (,75 basepairs), we were
unable to rigorously classify all OTUs, including #199, to species. In the Silva data-
base, there were 38 full-length 16S sequences with an exact match to the consensus
sequence of OTU #199. All were classified to genus Clostridium. RDP classified the
consensus sequence for OTU#199 as Clostridiaceae I with 99% confidence and the
sub-genus Clostridium sensu stricto with 52% confidence. Longer amplicons will be
required to narrow this taxonomic assignment in future work.
Statistics. Statistical tests are described in figure legends and were computed using
PRIMER v. 6, Microsoft Excel, Graphpad Prism, R v. 2.15.1 (http://www.R-
project.org), and/or SAS v. 9.2 (SAS Institute Inc., Cary, NC). All tests are two-tailed,
alpha 5 0.05.
For microbiota analyses, OTU abundances were standardized to relative abund-
ance, log-transformed, and analyzed with a Bray-Curtis similarity matrix using
PRIMER v. 6 (PRIMERe, Inc). Analysis of Similarity (ANOSIM) was used to test for
dissimilarity in community composition, and ordination plots were generated by
multidimensional scaling (MDS). ANOSIM was nested on cage for the luminal
microbiota; cage was not a factor for the mucosally-adherent microbiota as we
assessed just one representative animal per cage. Before performing ANOSIM, we
removed OTUs represented in , 25% of samples. Diversity was assessed by cal-
culating Shannon diversity index, Margalef richness index and Pielou evenness index.
For calculation of P-values for diversity in the luminal microbiota, the mean from all
mice within a cage was utilized as an observational replicate. To compare the
abundance of individual taxa between groups, we performed pairwise comparisons
within the mucosally-adherent microbiota by t test and in the luminal/stool micro-
biota by fitting a mixed effect linear model of the form: T 5 i 1 c1V 1 c2 G(V) 1 e
where T represents the Log Normalized Count; V represents treatment (VSL#3 or
non-VSL#3); G represents the Cage; i is the intercept; c1 and c2 are coefficients for
independent variables; e is the residual. This model takes into account the fact that
multiple cages are involved and could contribute to the variation detected between
samples38. VSL#3 was treated as a fixed effect while cage nested within VSL#3, the
term G(V) in the model, was considered a random effect. All P-values were corrected
for multiple testing using the Benjamini and Hochberg procedure39 ((n*p)/R where n
5 # taxa, p 5 test P-value, R 5 rank by raw P-value) at a false discovery rate (FDR)
threshold of 10%. Before performing pairwise comparisons, we excluded low
abundance taxa that contributed , 1%.
Baron & Kenny’s four steps approach40–42, the most widely used method to assess
causal mediation, was used to evaluate each OTU in the mucosally-adherent
microbiota for its potential mediation effect between VSL#3 and dysplasia. This
analysis was performed through four linear models using SAS v. 9.2. Model 1 tests that
VSL#3 is significantly associated with dysplasia score. Model 2 tests that the relative
abundance of the OTU is significantly associated with dysplasia. Model 3 tests the
VSL#3 effect on the relative abundance of the OTU (for OTUs found to have a
significant effect on dysplasia in model 2). Model 4 tests whether the bacterial taxon
(i.e. OTU#199) affects dysplasia without the influence of VSL#3, and whether VSL#3
affects dysplasia without the influence of OTU#199. Equations: Model 1, D 5 i1 1 c1V
1 e1; Model 2, D 5 i2 1 c2T 1 e2; Model 3, T 5 i3 1 c3V 1 e3; Model 4, D 5 i4 1 c4T
1 c5V 1 e4. D represents dysplasia score; V represents treatment (VSL#3 or non-
VSL#3); T represents the log-normalized relative abundance of a particular taxon
(OTU); i1, i2, i3, i4 are intercepts; c1, c2, c3, c4, c5 are coefficients for independent
variables; e1, e2, e3, e4 are residuals.
OTUs were considered as potential mediators if they met the three criteria
proposed by Baron & Kenny: (i) P-values from models 1–3 are significant, (ii) The
P-value for the VSL#3 effect in model 4 is less significant than in model 1 and (iii) The
P-value for the OTU relative abundance effect in model 4 remains significant. The
Benjamini and Hotchberg procedure was applied for multiple comparisons and FDR-
corrected P , 0.10 was considered significant. As all four models belong to one
analysis, a single P , 0.10 cutoff was applied. Each taxon was tested separately for its
mediation effect.
Inflammation PCR arrays. Inflammatory gene expression was evaluated using
SABiosciences array as described by us8. Briefly, RNA was extracted from distal colon
biopsies (4 per group) using phenol:chloroform, DNase treatment (Qiagen) and
RNeasy kit (Qiagen). 1 mg of RNA was transcribed to cDNA using RT2 First Strand
kit (Qiagen/SABiosciences). Expression of inflammatory mediators was assessed
using inflammation array PAMM-077 (Qiagen/SABiosciences). Data analysis was
performed with SABioscience RT2 Profiler PCR Array Data Analysis version 3.4
(Qiagen/SA Biosciences: http://pcrdataanalysis.sabiosciences.com/pcr/
arrayanalysis.ph) using the DDCt method after normalizing to five housekeeping
genes. Data are presented as fold changes for four individual VSL#3-treated mice,
relative to the mean of four SPF mice.
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